Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circulation. Author manuscript; available in PMC 2011 September 14.
Published in final edited form as:
PMCID: PMC3070356

Research Priorities in Hypertrophic Cardiomyopathy: Report of a Working Group of the National Heart Lung and Blood Institute

Thomas Force, M.D.,1,2 Robert O. Bonow, M.D.,3 Steven R. Houser, Ph.D.,4 R. John Solaro, Ph.D.,5 Ray E. Hershberger, M.D.,6 Bishow Adhikari, Ph.D.,7 Mark E. Anderson, M.D. Ph.D.,8 Robin Boineau, M.D.,7 Barry J. Byrne, M.D., Ph.D.,9 Thomas P. Cappola, M.D.,10 Raghu Kalluri, M.D., Ph.D.,11 Martin M. LeWinter, M.D.,12 Martin S. Maron, M.D.,13 Jeffery D. Molkentin, Ph.D.,14 Steve R. Ommen, M.D.,15 Michael Regnier, Ph.D.,16 W. H. Wilson Tang, M.D.,17 Rong Tian, Ph.D.,18 Marvin A. Konstam, M.D.,13 Barry J. Maron, M.D.,19 and Christine E. Seidman, M.D.20


Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by left ventricular (LV) hypertrophy without dilatation and without apparent cause (i.e. occurs in the absence of severe hypertension, aortic stenosis, or other cardiac or systemic diseases that might cause LV hypertrophy. Numerous excellent reviews and consensus documents provide a wealth of additional background.18 HCM is the leading cause of sudden death in young people and leads to significant disability in survivors. It is caused by mutations in genes that encode components of the sarcomere. Cardiomyocyte and cardiac hypertrophy, myocyte disarray, interstitial and replacement fibrosis, and dysplastic intramyocardial arterioles characterize the pathology of HCM. Clinical manifestations include impaired diastolic function, heart failure, tachyarrhythmia (both atrial and ventricular), and sudden death. At present, there is a lack of understanding of how the mutations in genes encoding sarcomere proteins lead to the phenotypes described above. Current therapeutic approaches have focused on the prevention of sudden death with ICD placement in high-risk patients. But medical therapies have largely focused on alleviating symptoms of the disease, not on altering its natural history. This Working Group of the NHLBI brought together clinical, translational, and basic scientists with the over-arching goal being to identify novel strategies to prevent the phenotypic expression of disease. Herein, we identify research initiatives that will hopefully lead to novel therapeutic approaches for patients with HCM.


The epidemiology of HCM suggests that it is present in approximately 1 in 500 adults.9 Due to the delay in phenotypic expression of the disease, HCM is not commonly recognized clinically in young children, but when it is, it is much more frequently recognized in males.10 This is likely due to greater penetrance in young males.11, 12 HCM is under-diagnosed clinically in African Americans and women, yet women tend to present with more marked heart failure than men when they are diagnosed later in life.13, 14 There is no overall difference in mortality, including sudden cardiac death (SCD), between men and women, though SCD on the athletic field predominantly occurs in males.

Genetic cause

Extensive investigation has shown that at least 50% of HCM can be traced to a specific genetic cause. This probably underestimates the true percentage of genetically based HCM since current mutation screening platforms typically examine only 8–10 genes, due to unfavorable cost-benefit assessments. For example, current platforms do not examine titin (due to its size) or myozenin-2 (due to relatively few mutations having been defined in this gene).15 Moreover when strict clinical criteria are used for diagnosis, including family history, mutation detection approaches 70%.

HCM is a genetic disease of sarcomere proteins,5, 16 with mutations in the genes encoding beta myosin heavy chain (MYH7) and myosin binding protein C (MYBPC3) accounting for approximately 80% – 85% of cases with identified mutations in most series4, 1719. Mutations in the troponins, cardiac troponin T (TNNT2) and troponin I (TNNI3), and alpha-tropomyosin (TPM1), are also relatively common, collectively representing 10–15% of additional genetic causes for all HCM cases 4, 17, 19. These and the myosin light chains (MYL2, MYL3), and alpha-cardiac actin (ACTC) are the eight genes most commonly involved in HCM.

Rare genetic causes

Mutations in several other genes that encode sarcomere or sarcomere-related proteins have been implicated in HCM, including cardiac troponin C (TNNC1), alpha-myosin heavy chain (MYH6), and cardiac myosin light chain kinase 2 (MYLK2). In addition several other genes encoding non-sarcomere proteins including caveolin 3 (CAV3), calreticulin (CALR3), junctophilin-2 (JPH2), phospholamban (PLN), and the mitochondrial tRNA-encoding genes MTTG and MTTI, produce clinical features that mimic HCM.4, 20 The relationship of HCM caused by sarcomere protein gene mutations to these disorders is unclear.5, 16

Unknown causes

The apparent absence of mutations in patients with a clinical diagnosis of HCM indicates an important gap in our knowledge. Mutation testing can be particularly uninformative in three clinical scenarios in which family history is negative: 1) hypertrophy that occurs very early in childhood, 2) hypertrophy that is only recognized after middle age, and 3) hypertrophy that is limited to the ventricular apex.21 The etiology of these conditions is not clear.

Disease mechanisms

The disease mechanisms of HCM remain incompletely understood. Postulated mechanisms include 1) a dominant negative function (i.e. a ‘poison peptide,’ wherein the mutant gene encodes a protein that interferes with the function of the normal allele), 2) haploinsufficiency (leading to an insufficient quantity of the normally functioning sarcomere protein), and/or 3) impaired myocardial energetics and decreased energy reserve.8, 22, 23 The lack of a definitive link between mutations and an understanding of the pathogenesis/molecular mechanisms driving the expression of the HCM phenotype is a significant gap in our understanding of the disease.

Clinical genetics

Allelic heterogeneity (each family having a so-called ‘private mutation’) is particularly common in HCM. Approximately 500 mutations have been noted in the medical literature but the number of identified mutations in various private databases suggest the true number is more than 1000. HCM demonstrates age-dependent penetrance, affecting 50–80% and 95% of individuals by age 30 and ages 50–60, respectively.24 Recent estimates of 1% annual mortality in HCM differ significantly from earlier estimates (3–6%) that were based upon referral populations of high-risk groups to HCM centers.2527 Survival to 75 years or beyond has been estimated in approximately 25% of an unselected HCM cohort.28

Compound heterozygosity

Two to five percent of patients with HCM harbor two mutations (compound or double heterozygosity) or are homozygous for a mutation,4, 18, 29, 30 and these patients display more severe and/or earlier onset of disease.29, 30

Genotype/phenotype relationships

Despite the significant clinical heterogeneity observed even for the same mutation within families or between families,3135 and the variable penetrance, which alters clinical onset and severity of disease, genotype/phenotype relationships of sarcomere gene mutations have clearly advanced our understanding of the disease and, in some cases, have allowed identification of relatively low vs. high risk patients. 36, 37 Some genotype/phenotype relationships that have stood the test of time include MYH7 mutations which are associated with earlier onset and more extensive hypertrophy.8, 33, 35 More specifically the myosin 403 mutation is associated with increased risk of heart failure and sudden death, and the myosin 719 mutation leads to a marked increase in heart failure. Others include the relatively limited hypertrophic response with TNNT2 mutations34, 38, 39, and the incomplete penetrance and relatively later onset of HCM from MYBPC3 mutations 31, 36, 40. That said, multiple poorly understood mechanisms contribute to heterogeneity of presentation, and these include environmental inputs, gender,10 as well as genetic and epigenetic modifiers.

Key morphologic and clinical components of genetically-mediated HCM

Cardiomyocyte and cardiac hypertrophy, myocyte disarray, interstitial and replacement fibrosis, and dysplastic intramyocardial arterioles characterize the pathology of HCM. Clinical manifestations include impaired diastolic function, tachyarrhythmia (both atrial and ventricular), and sudden death. 4144 Accepted risk factors for sudden cardiac death include: prior cardiac arrest from ventricular fibrillation, spontaneous sustained ventricular tachycardia, family history of premature sudden death, unexplained syncope, LV wall thickness ≥ 30 mm, abnormal blood pressure response to exercise, and nonsustained ventricular tachycardia.28, 43 Additional predictors include the presence of left ventricular apical aneurysms and the end stage of disease.45, 46

A consensus document1 and review47 of clinical management of arrhythmias and sudden cardiac death in HCM are available. Clinically apparent AF develops in at least 20% of patients with HCM48 but the true incidence is likely higher than that. AF is a risk factor for thromboembolic disease including stroke.1 Molecular mechanisms regulating the phenotypic expression of the various pathologies, and how these might drive arrhythmogenesis in HCM are poorly understood.

Genetic causes of LV hypertrophy not involving sarcomere mutations

LV hypertrophy can result from gene mutations that alter proteins with functions that are unrelated to the sarcomere. These include Fabry disease, glycogen storage disorders (PRKAG2 cardiomyopathy and Pompe disease) lysosomal disorders (LAMP2 cardiomyopathy), and several syndromes (i.e., Noonan, LEOPARD, and Costello). The clinical manifestations and patient courses associated with these are different from HCM 8, 17, 4951 These phenocopies are not discussed further herein.

Rationale for investing in research on HCM

The rationale for investing in research in HCM is supported by the following: 1) HCM is the most common genetic heart disease and affects individuals at every age; 2) HCM is the most common cause of sudden death in young people; 3) HCM is an important cause of heart failure disability; 4) HCM can be viewed as a paradigm for the potential opportunities provided by harnessing modern genetic science in medicine to make gene-based diagnosis and prediction a reality; 5) Gaps in our basic understanding of mechanisms of disease are substantial, but already insights provided by studies in patients and in animal models of HCM suggest creative strategies to alter the natural history of this disease; 6) These insights also promise a greater understanding of the molecular pathophysiology of other, non-genetic causes of hypertrophy. Thus we believe that there are unparalleled opportunities in the immediate and near future to translate basic insights about HCM into new clinical models for diagnosis, prevention and therapy.

Critical deficits in our understanding of HCM pathogenesis define research initiatives

In the on-line supplement to this document, we define key deficits in our understanding of HCM, thereby leading into a delineation of research initiatives for the future. The areas of research will be broken down into Clinical, Translational, and Basic sections, but these divisions are clearly arbitrary and only serve as an organizational (and not operational) tool. In fact we will strive to maintain connections among the three divisions, focusing on common deficits in our understanding.

Supplementary Material



Funding sources:

The following receive research grants from National Institutes of Health (NIH), Howard Hughes Medical Institute (HHMI), the Fondation Leducq (FL), The American Heart Association (AHA) and/or other sources:

Thomas Force (NIH, The Kahn Foundation, the Scarperi Family, and AHA)

Mark E. Anderson (NIH, FL)

Steven Houser (NIH)

Martin LeWinter (NIH)

Jeffery Molkentin (NIH, HHMI, and FL)

Christine Seidman (NIH, HHMI, and FL

R. John Solaro (NIH)

Barry Byrne (NIH)

Martin Maron (NIH)

W.H. Wilson Tang (NIH)

Rong Tian (NIH)

Michael Regnier (NIH)

Ray E. Hershberger (NIH)

Robert O. Bonow (NIH)

Thomas P. Cappola (NIH)

Raghu Kalluri (NIH)


All other authors have declared that they have nothing to disclose

Conflict of interest disclosures

R. John Solaro, Scientific Advisory Board, (Cytokinetics, Inc.)

Barry J. Byrnem, Honoraria, (Amicus Therapeutics)

Ownership interest, (AGTC, Inc.)

Thomas P. Cappola, Other research support (Abbot Diagnostics)

Martin Maron, Consultant/Advisory Board (PGX Health, Genzyme)

W.H. Wilson Tang, Other research support (Abbot Labs)

Consultant (Medtronic Inc.)

Barry Maron, Research Grant (Medtronic, Inc.)

Honoraria (Medtronic, Inc.)

Consultant (Gene Dx)

Marvin A. Konstam, Consultancy and/or research support from Merck and Co., Boehringer-Ingelheim, Johnson and Johnson, and Trevena


1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, 3rd, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687–1713. [PubMed]
2. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA. 2002;287:1308–1320. [PubMed]
3. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006;113:e858–862. [PubMed]
4. Marian AJ. Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol. 2008;23:199–205. [PMC free article] [PubMed]
5. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816. [PubMed]
6. Taylor MR, Carniel E, Mestroni L. Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing. Expert Rev Mol Diagn. 2004;4:99–113. [PubMed]
7. Ashrafian H, Watkins H. Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. J Am Coll Cardiol. 2007;49:1251–1264. [PubMed]
8. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5:158–168. [PubMed]
9. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Ehocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–789. [PubMed]
10. Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, Towbin JA, Seidman JG, Seidman CE. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899–1908. [PMC free article] [PubMed]
11. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647–1655. [PubMed]
12. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, Davis AM, Kahler SG, Chow CW, Wilkinson JL, Weintraub RG. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348:1639–1646. [PubMed]
13. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480–487. [PubMed]
14. Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, Sherrid MV. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:974–980. [PubMed]
15. Osio A, Tan L, Chen SN, Lombardi R, Nagueh SF, Shete S, Roberts R, Willerson JT, Marian AJ. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res. 2007;100:766–768. [PMC free article] [PubMed]
16. Maron BJ, Seidman CE, Ackerman MJ, Towbin JA, Maron MS, Ommen SR, Nishimura RA, Gersh BJ. How should hypertrophic cardiomyopathy be classified?: What’s in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet. 2009;2:81–85. discussion 86. [PubMed]
17. Cirino AL, Ho C. Familial Hypertrophic Cardiomyopathy Overview. Copyright, University of Washington; [Accessed August 13, 2008]. 2008. [Available at]. Available at:
18. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227–2232. [PubMed]
19. Ackerman MJ. Genetic testing for risk stratification in hypertrophic cardiomyopathy and long QT syndrome: fact or fiction? Curr Opin Cardiol. 2005;20:175–181. [PubMed]
20. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol. 2007;22:193–199. [PubMed]
21. Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid M, Ho CY, Barr S, Karim A, Olson TM, Kamisago M, Seidman JG, Seidman CE. Gene mutations in apical hypertrophic cardiomyopathy. Circulation. 2005;112:2805–2811. [PubMed]
22. Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res. 2009;105:219–222. [PubMed]
23. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–1782. [PubMed]
24. Charron P. Clinical genetics in cardiology. Heart. 2006;92:1172–1176. [PMC free article] [PubMed]
25. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92:785–791. [PMC free article] [PubMed]
26. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281:650–655. [PubMed]
27. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858–864. [PubMed]
28. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003;42:882–888. [PubMed]
29. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59. [PMC free article] [PubMed]
30. Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, Ommen SR, Theis JL, Vaubel RA, Re F, Armentano C, Poggesi C, Torricelli F, Cecchi F. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83:630–638. [PubMed]
31. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagege A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998;97:2230–2236. [PubMed]
32. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Bonne G, Carrier L, Tesson F, Bouhour JB, Buzzi JC, Feingold J, Schwartz K, Komajda M. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J. 1998;19:139–145. [PubMed]
33. Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ, Ackerman MJ. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:602–610. [PubMed]
34. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O’Donoghue A, Spirito P, Matsumori A, Moravec C, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058–1064. [PubMed]
35. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–1114. [PubMed]
36. Erdmann J, Raible J, Maki-Abadi J, Hummel M, Hammann J, Wollnik B, Frantz E, Fleck E, Hetzer R, Regitz-Zagrosek V. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2001;38:322–330. [PubMed]
37. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:1903–1910. [PubMed]
38. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997;29:549–555. [PubMed]
39. Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R, Gimeno JR, Elliott P, McKenna WJ. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest. 2003;111:209–216. [PMC free article] [PubMed]
40. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–1257. [PubMed]
41. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354. [PubMed]
42. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC, Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J Am Coll Cardiol. 2006;48:e247–346. [PubMed]
43. Miller MA, Gomes JA, Fuster V. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2007;4:667–676. [PubMed]
44. Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Camici PG. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:866–875. [PubMed]
45. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216–225. [PubMed]
46. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118:1541–1549. [PubMed]
47. Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117:429–439. [PubMed]
48. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517–2524. [PubMed]
49. Hershberger R, Cowan J, Morales A, Siegfried J. Progress with genetic cardiomyopathies: Screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail. 2009;2:253–261. [PMC free article] [PubMed]
50. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29:992–1006. [PubMed]
51. Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman J, Seidman CE. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009;301:1253–1259. [PubMed]